Kalev Kask, Ph.D., Chief Executive Officer
Edmund "Ned" M. Olivier, Chairman, Founding General Partner, Oxford Bioscience Partners
Ned Olivier has extensive investment experience in venture capital and outstanding investment performance. He was a co-founder and General Partner of Oxford Bioscience Partners I and II L.P. Prior to entering venture capital with Fairfield/Steuben Venture Partners in 1984, he managed domestic and international operations for Diamond Shamrock, Corning Glass Works and Conoco Chemicals. At Diamond Shamrock he served as Vice President of Technology and Planning. At Corning he was a member of the Corporate Executive Committee and Corporate Vice President and General Manager of the Scientific Products Division, where he initiated Corning's entry into biotechnology. At Conoco Chemicals he was managing Director, Europe. He is a Life Fellow and member of the International Council of the Salk Institute.
Mir Imran, Venture Partner and Senior Advisor, Draper Fisher Jurvetson ePlanet Ventures. Mir Imran focuses on life sciences and technology investments on a global basis. Mr. Imran is the Founder and President of InCube, Inc., a Silicon Valley incubator for medical and Internet companies. Through this incubator, and prior to its establishment, Mr. Imran founded numerous medical and high technology companies. Mr. Imran currently serves as a Director for Surface Genesis, CardioVasc, NovaSonics, JStreetData.com and IntraPace. Mr. Imran was also a Founder and Director of Percusurge, a marketer and developer of circulatory system devices, which was eventually acquired by Medtronic in 2000, as well as of Cardiac Pathways, a developer of catheters that was acquired by Boston Scientific in 2001. Mr. Imran developed numerous medical devices and obtained close to 200 patents in his name. One of his high profile medical inventions is the EEG monitoring sensor array that the American astronaut John Glenn used on his latest space mission. In 1990, Mr. Imran invented a basket catheter that obtains multiple ECG signals simultaneously from various areas of the heart. In 1992, he developed a low-pressure balloon and aspirator system for use in catheter based interventions. Mr. Imran is also an active angel investor and a special limited partner in several prominent venture funds.
Robb Doub, Managing Director, New Markets Fund
Mr. Doub has served as the Vice President of Investments of SEAF, where his principal role was to advise the Fund Managers of the SEAF Funds in investment structuring and in strategic business issues of the portfolio companies of the Country Funds. From September 1995 until May of 1997, Mr. Doub worked in Poland as an Investment Officer of CARESBAC-Polska, a SEAF managed fund. Prior to his service in Poland, Mr. Doub worked as an investment analyst for the Calvert Group in Washington DC and New Enterprise Associates in Baltimore, Maryland. His prior investments include Asper Biotech, an Estonian genotyping technology company.
Peeter Saks, Managing Partner of BaltCap and Chairman of Suprema Securities
Mr. Saks has worked in investment banking and private equity since 1994. After a brief career at PWC, he formed Talinvest, one of Estonia's earliest investment banks, and laid the foundations for Suprema that made its name in a series of successful deals in the first wave of privatization in Estonia. Mr. Saks oversaw an expansion into Latvia and Lithuania, steered Suprema successfully through the 1998 Russian crisis giving it the strongest brand in corporate finance and capital markets in the Baltics. In 2002 Suprema was bought by Finland's Evli Bank - a move that gave it stronger access to the Nordic capital and investor base. Mr. Saks has been involved in Baltcap since its inception as an advisor thereafter as an investor into the management company and becoming a board member, and finally buying the majority stake and becoming managing director 2005. He has also served on the Board of EBRD funded Baltic Post-Privatization Fund and advised other venture funds. Mr. Saks was a founding member of the Tallinn Stock Exchange in 1995. He has graduated form Tallinn Technical University and completed studies at the Henley Management College and INSEAD.
Agnes LeSaux-Narjoz,, Managing Director, Biobank Technology Ventures
Besides managing investments on behalf of Biobank Technology Ventures, Ms. LeSaux-Narjoz co-founded Endocube SA and was its CEO from 2004 to 2006. Before that she served as an Executive Officer and Vice President of Marketing and Commercial Development of Genset SA from 1989 until its sale to Serono in 2000, where her principal role was to build Genset's global synthetic DNA business from scratch to one of the top providers in the world achieving 50% annual sales growth against highly competitive industry background. Prior to Genset, she was in charge of business development at Transgene SA and worked with several investment firms.
